Cargando…

Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study

PURPOSE: Neurofibromatosis 1 (NF1) is an autosomal dominant condition caused by pathogenic variants of the NF1 gene. A markedly increased risk of breast cancer is associated with NF1. We have determined the breast cancer survival and risk of contralateral breast cancer in NF1. METHODS: We included 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, D. Gareth R., Kallionpää, Roope A., Clementi, Maurizio, Trevisson, Eva, Mautner, Victor-Felix, Howell, Sacha J., Lewis, Lauren, Zehou, Ouidad, Peltonen, Sirkku, Brunello, Antonella, Harkness, Elaine F., Wolkenstein, Pierre, Peltonen, Juha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000349/
https://www.ncbi.nlm.nih.gov/pubmed/31495828
http://dx.doi.org/10.1038/s41436-019-0651-6
_version_ 1783494021649268736
author Evans, D. Gareth R.
Kallionpää, Roope A.
Clementi, Maurizio
Trevisson, Eva
Mautner, Victor-Felix
Howell, Sacha J.
Lewis, Lauren
Zehou, Ouidad
Peltonen, Sirkku
Brunello, Antonella
Harkness, Elaine F.
Wolkenstein, Pierre
Peltonen, Juha
author_facet Evans, D. Gareth R.
Kallionpää, Roope A.
Clementi, Maurizio
Trevisson, Eva
Mautner, Victor-Felix
Howell, Sacha J.
Lewis, Lauren
Zehou, Ouidad
Peltonen, Sirkku
Brunello, Antonella
Harkness, Elaine F.
Wolkenstein, Pierre
Peltonen, Juha
author_sort Evans, D. Gareth R.
collection PubMed
description PURPOSE: Neurofibromatosis 1 (NF1) is an autosomal dominant condition caused by pathogenic variants of the NF1 gene. A markedly increased risk of breast cancer is associated with NF1. We have determined the breast cancer survival and risk of contralateral breast cancer in NF1. METHODS: We included 142 women with NF1 and breast cancer from five cohorts in Europe and 335 women without NF1 screened for other familial breast cancers. Risk of contralateral breast cancer and death were assessed by Kaplan–Meier analysis with delayed entry. RESULTS: One hundred forty-two women with NF1 were diagnosed for breast cancer at a median age of 46.9 years (range 27.0–84.3 years) and then followed up for 1235 person-years (mean = 8.70 years). Twelve women had contralateral breast cancer with a rate of 10.5 per 1000 years. Cumulative risk for contralateral breast cancer was 26.5% in 20 years. Five and 10-year all-cause survival was 64.9% (95% confidence interval [CI] = 54.8–76.8) and 49.8% (95%CI = 39.3–63.0). Breast cancer–specific 10-year survival was 64.2% (95% CI = 53.5–77.0%) compared with 91.2% (95% CI = 87.3–95.2%) in the non-NF1 age-matched population at increased risk of breast cancer. CONCLUSION: Women with NF1 have a substantial contralateral breast cancer incidence and poor survival. Early start of breast cancer screening may be a way to improve the survival.
format Online
Article
Text
id pubmed-7000349
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-70003492020-02-06 Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study Evans, D. Gareth R. Kallionpää, Roope A. Clementi, Maurizio Trevisson, Eva Mautner, Victor-Felix Howell, Sacha J. Lewis, Lauren Zehou, Ouidad Peltonen, Sirkku Brunello, Antonella Harkness, Elaine F. Wolkenstein, Pierre Peltonen, Juha Genet Med Article PURPOSE: Neurofibromatosis 1 (NF1) is an autosomal dominant condition caused by pathogenic variants of the NF1 gene. A markedly increased risk of breast cancer is associated with NF1. We have determined the breast cancer survival and risk of contralateral breast cancer in NF1. METHODS: We included 142 women with NF1 and breast cancer from five cohorts in Europe and 335 women without NF1 screened for other familial breast cancers. Risk of contralateral breast cancer and death were assessed by Kaplan–Meier analysis with delayed entry. RESULTS: One hundred forty-two women with NF1 were diagnosed for breast cancer at a median age of 46.9 years (range 27.0–84.3 years) and then followed up for 1235 person-years (mean = 8.70 years). Twelve women had contralateral breast cancer with a rate of 10.5 per 1000 years. Cumulative risk for contralateral breast cancer was 26.5% in 20 years. Five and 10-year all-cause survival was 64.9% (95% confidence interval [CI] = 54.8–76.8) and 49.8% (95%CI = 39.3–63.0). Breast cancer–specific 10-year survival was 64.2% (95% CI = 53.5–77.0%) compared with 91.2% (95% CI = 87.3–95.2%) in the non-NF1 age-matched population at increased risk of breast cancer. CONCLUSION: Women with NF1 have a substantial contralateral breast cancer incidence and poor survival. Early start of breast cancer screening may be a way to improve the survival. Nature Publishing Group US 2019-09-09 2020 /pmc/articles/PMC7000349/ /pubmed/31495828 http://dx.doi.org/10.1038/s41436-019-0651-6 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Article
Evans, D. Gareth R.
Kallionpää, Roope A.
Clementi, Maurizio
Trevisson, Eva
Mautner, Victor-Felix
Howell, Sacha J.
Lewis, Lauren
Zehou, Ouidad
Peltonen, Sirkku
Brunello, Antonella
Harkness, Elaine F.
Wolkenstein, Pierre
Peltonen, Juha
Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
title Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
title_full Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
title_fullStr Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
title_full_unstemmed Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
title_short Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
title_sort breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000349/
https://www.ncbi.nlm.nih.gov/pubmed/31495828
http://dx.doi.org/10.1038/s41436-019-0651-6
work_keys_str_mv AT evansdgarethr breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT kallionpaaroopea breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT clementimaurizio breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT trevissoneva breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT mautnervictorfelix breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT howellsachaj breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT lewislauren breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT zehououidad breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT peltonensirkku breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT brunelloantonella breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT harknesselainef breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT wolkensteinpierre breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy
AT peltonenjuha breastcancerinneurofibromatosis1survivalandriskofcontralateralbreastcancerinafivecountrycohortstudy